NASDAQ, OMER - Omeros Corp
We are a clinical-stage biopharmaceutical company committed to discovering,
developing and commercializing products focused on inflammation and disorders of
the central nervous system. Our most clinically advanced product candidates are
derived from our proprietary PharmacoSurgerytm platform designed to improve
clinical outcomes of patients undergoing arthroscopic, ophthalmological,
urological and other surgical and medical procedures. Our PharmacoSurgery
platform is based on low-dose combinations of therapeutic agents delivered
directly to the surgical site throughout the duration of the procedure to
preemptively inhibit inflammation and other problems caused by surgical trauma
and to provide clinical benefits both during and after surgery. We currently
have five ongoing clinical development programs, including four from our
PharmacoSurgery platform and one from our Addiction program. ...
Read SEC Filing on NASDAQ.com »